WordNet

of parents and children; related by adoption; "adoptive parents"
therapy designed to produce immunity to a disease or to enhance resistance by the immune system

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 移植後のリンパ球増殖性疾患の治療および予防 treatment and prevention of post transplant lymphoproliferative disorders
2. 再発または難治性古典的ホジキンリンパ腫に対するセカンドラインおよびサードライン化学療法レジメンおよび生物学的療法 second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical hodgkin lymphoma
3. 再発性および転移性鼻咽頭癌の治療 treatment of recurrent and metastatic nasopharyngeal carcinoma
4. 慢性B型肝炎ウイルス感染の試験研究中の治療 investigational treatments of chronic hepatitis b virus infection
5. 腎細胞癌の免疫療法 immunotherapy of renal cell carcinoma

8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015-May 20-22, Vancouver, Canada.

Boudreau JE1, Wouters MC2, Krawczyk CM3.
Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2016 Jan 12. [Epub ahead of print]
PMID 26759005

Versatile strategy for controlling the specificity and activity of engineered T cells.

Ma JS1, Kim JY1, Kazane SA1, Choi SH2, Yun HY2, Kim MS1, Rodgers DT1, Pugh HM1, Singer O1, Sun SB1, Fonslow BR3, Kochenderfer JN4, Wright TM1, Schultz PG5, Young TS6, Kim CH6, Cao Y2.
Proceedings of the National Academy of Sciences of the United States of America.Proc Natl Acad Sci U S A.2016 Jan 12. pii: 201524193. [Epub ahead of print]
The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical efficacy, the general application of current CAR-T-cell therapy is limited by serious treatment-related toxicities. One approach
PMID 26759368

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.

Gross G1,2,3, Eshhar Z3,4.
Annual review of pharmacology and toxicology.Annu Rev Pharmacol Toxicol.2016 Jan 6;56:59-83. doi: 10.1146/annurev-pharmtox-010814-124844.
A chimeric antigen receptor (CAR) is a recombinant fusion protein combining an antibody-derived targeting fragment with signaling domains capable of activating T cells. Recent early-phase clinical trials have demonstrated the remarkable ability of CAR-modified T cells to eliminate B cell malignancie
PMID 26738472